Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2011-10-28 | Topotarget (Denmark) Multimeric Biotherapeutics (USA) | multimeric TNF superfamily ligands (TNFSFs) | licensing |
Licensing agreement | ||
2011-10-28 | Protagen (Germany) Charles River (USA) | protein analytics from detailed protein characterization to stability and lot release testing | commercialisation |
Commercialisation agreement | ||
2011-10-28 | Atlab Pharma (France) BZL Biologics (USA) | 177Lu-J591 | licensing |
Cancer - Oncology | Licensing agreement | |
2011-10-27 | Oncodesign (France) Taconic (USA) | pre-clinical oncology in vivo solutions for researchers | development |
Cancer - Oncology | Establishment of a new subsidiary in the EU | |
2011-10-26 | Sanofi (France) Immune Design Corp (USA) | Glucopyranosyl Lipid Adjuvant (GLA) technology | allergy | R&D |
Allergic diseases - Immunological diseases | R&D agreement |
2011-10-25 | Lonza (Switzerland) Genmab (Denmark) | HuMax-TF® | \ | development
|
Cancer Oncology | Production agreement |
2011-10-25 | Probiogen (Germany) Inhibrx (USA) | GlymaxX® Antibody Glyco-Engineering technology | licensing |
Licensing agreement | ||
2011-10-24 | Encap Drug Delivery (UK) Lena Nanoceutics (UK) | drug delivery technology (Nano-Capsules) combining nano-particle engineering technology with liquid filled hard capsule technology | development |
Development agreement | ||
2011-10-24 | Silence Therapeutics (UK) Mirna Therapeutics (USA) | novel microRNAs candidate drugs based on AtuPLEX™ and DBTC delivery systems | undisclosed | R&D |
R&D agreement | |
2011-10-20 | Ipsen (France) Syntaxin (UK) | botulinum toxins | research - R&D - development - commercialisation | R&D agreement | ||
2011-10-20 | Evotec (Germany) Apeiron Biologics (Austria) | active molecules interacting with Cbl-b target | research - R&D | Cancer - Oncology | R&D agreement | |
2011-10-18 | Flamel Technologies (France) GSK (UK) | Coreg CR® microparticles | supply | |||
2011-10-17 | Angel Biotechnology (UK) Materia Medica Holding (Russia) | joint-venture manufacturing production |
Production agreement | |||
2011-10-17 | Agilent Technologies (USA) Oxford Gene Technology (UK) | oligonucleotide microarrays and SureSelect target enrichment products for next-generation sequencing | Collaboration agreement | |||
2011-10-13 | Eagle Pharmaceuticals (USA) Flamel Technologies (France) | Medusa-based hydrogel depot formulation of tigecycline | development |
Infectious diseases | Development agreement | |
2011-10-12 | Galapagos (Belgium) Chiesi (Italy) | research - R&D | R&D agreement | |||
2011-10-12 | Bayer HealthCare (Germany) Onyx Pharmaceuticals (USA) | Nexavar® (sorafenib) and regorafenib | liver cancer, advanced kidney cancer, hepatocellular carcinoma, advanced renal cell carcinoma | development |
Cancer - Oncology | Development agreement |
2011-10-12 | deCODE genetics (Iceland) Pfizer (USA - NY) | variants in the human genome that confer risk of systemic lupus erythematosis. | systemic lupus erythematosis | R&D |
Autoimmune diseases | R&D agreement |
2011-10-12 | Faron Pharmaceuticals (Finland) Biovian (Finland) | humanized anti-Clever-1 antibody FP-1304 | development |
Cancer - Oncology | Development agreement | |
2011-10-11 | Karyopharm Therapeutics (USA) Katholieke Universiteit Leuven (Belgium) | Selective Inhibitors of Nuclear Export (SINE) modulators of the CRM1 protein | cancer, autoimmune diseases and viral diseases | research - R&D | Cancer - Oncology - Autoimmune diseases - Infectious diseases | R&D agreement |